Should I buy or sell Co-Diagnostics stock right now?

1 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Co-Diagnostics in the last twelve months. There are currently 1 hold rating for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" CODX shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in CODX, but not buy additional shares or sell existing shares. View CODX analyst ratings or view top-rated stocks .

What is Co-Diagnostics' stock price target for 2024?

1 brokerages have issued 12 month price targets for Co-Diagnostics' stock. Their CODX share price targets range from $2.50 to $2.50. On average, they anticipate the company's stock price to reach $2.50 in the next year. This suggests a possible upside of 117.4% from the stock's current price. View analysts price targets for CODX or view top-rated stocks among Wall Street analysts .

How have CODX shares performed in 2024?

Co-Diagnostics' stock was trading at $1.33 at the start of the year. Since then, CODX stock has decreased by 13.5% and is now trading at $1.15. View the best growth stocks for 2024 here .

Are investors shorting Co-Diagnostics?

Co-Diagnostics saw a increase in short interest during the month of March. As of March 31st, there was short interest totaling 496,500 shares, an increase of 30.1% from the March 15th total of 381,500 shares. Based on an average daily volume of 66,300 shares, the days-to-cover ratio is presently 7.5 days. View Co-Diagnostics' Short Interest .

When is Co-Diagnostics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, May 9th 2024. View our CODX earnings forecast .

How were Co-Diagnostics' earnings last quarter?

Co-Diagnostics, Inc. (NASDAQ:CODX) announced its quarterly earnings results on Thursday, March, 14th. The company reported ($0.50) earnings per share (EPS) for the quarter. The business earned $3.56 million during the quarter, compared to analyst estimates of $3.63 million. Co-Diagnostics had a negative net margin of 518.69% and a negative trailing twelve-month return on equity of 35.37%.

What other stocks do shareholders of Co-Diagnostics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Co-Diagnostics investors own include Inovio Pharmaceuticals (INO) , Novavax (NVAX) , Moderna (MRNA) , Vaxart (VXRT) , Gilead Sciences (GILD) , Sorrento Therapeutics (SRNE) , iBio (IBIO) , Advanced Micro Devices (AMD) , Pfizer (PFE) and Johnson & Johnson (JNJ) .

When did Co-Diagnostics IPO?

Co-Diagnostics (CODX) raised $9 million in an initial public offering on Thursday, July 13th 2017. The company issued 1,300,000 shares at a price of $6.35-$6.75 per share. WallachBeth Capital and Network 1 Securities served as the underwriters for the IPO.

Who are Co-Diagnostics' major shareholders?

Co-Diagnostics' stock is owned by a variety of institutional and retail investors. Top institutional shareholders include SMI Advisory Services LLC (0.12%). Insiders that own company stock include Brian Lee Brown, Eugene Durenard and Reed L Benson . View institutional ownership trends .

How do I buy shares of Co-Diagnostics?

Shares of CODX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here .

NASDAQ:CODX

Co-Diagnostics (CODX) Stock Price, News & Analysis

→ Forget Bitcoin. Crypto Millionaire Predicts 8,788% Gains For THIS (From Paradigm Press) (Ad)

Free CODX Stock Alerts

$1.15

-0.01 (-0.86%)

(As of 04/19/2024 ET)

Compare

Today's Range: $1.14
▼
$1.17
50-Day Range: $1.06
▼
$1.27
52-Week Range: $0.98
▼
$1.89

Volume: 18,403 shs
Average Volume: 66,566 shs
Market Capitalization: $35.95 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $2.50

Get Co-Diagnostics alerts:

Co-Diagnostics MarketRank™ Stock Analysis

Analyst Rating: Hold
2.00 Rating Score
Upside/Downside: 117.4% Upside
$2.50 Price Target
Short Interest: Bearish
1.59% of Shares Sold Short
Dividend Strength: N/A
Sustainability: -1.10
Upright™ Environmental Score
News Sentiment: N/A
Insider Trading: N/A
Proj. Earnings Growth: N/A

Overall MarketRank^™

New Rank-Based ScoringMarketRank^™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

2.75 out of 5 stars

Medical Sector

415th out of 911 stocks

Surgical & Medical Instruments Industry

48th out of 97 stocks

3.0

Analyst's Opinion

Consensus Rating
Co-Diagnostics has received a consensus rating of Hold. The company's average rating score is 2.00, and is based on no buy ratings, 1 hold rating, and no sell ratings.
Amount of Analyst Coverage
Co-Diagnostics has only been the subject of 1 research reports in the past 90 days.

2.0

Short Interest

Percentage of Shares Shorted
1.59% of the outstanding shares of Co-Diagnostics have been sold short.
Short Interest Ratio / Days to Cover
Co-Diagnostics has a short interest ratio ("days to cover") of 7.5.
Change versus previous month
Short interest in Co-Diagnostics has recently increased by 30.14%, indicating that investor sentiment is decreasing significantly.

0.0

Dividend Strength

Dividend Yield
Co-Diagnostics does not currently pay a dividend.
Dividend Growth
Co-Diagnostics does not have a long track record of dividend growth.

4.4

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
Co-Diagnostics has received a 67.43% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is mostly driven by its "Diagnostic test kits", "Infectious disease diagnostics systems", and "PCR machines" products. See details.
Environmental Sustainability
The Environmental Impact score for Co-Diagnostics is -1.10.

0.6

News and Social Media Coverage

News Coverage This Week
MarketBeat has tracked 1 news article for Co-Diagnostics this week, compared to 1 article on an average week.
Search Interest
3 people have searched for CODX on MarketBeat in the last 30 days. This is an increase of 50% compared to the previous 30 days.
MarketBeat Follows
Only 1 people have added Co-Diagnostics to their MarketBeat watchlist in the last 30 days. This is a decrease of -50% compared to the previous 30 days.

0.0

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Co-Diagnostics insiders have not sold or bought any company stock.
Percentage Held by Insiders
Only 2.40% of the stock of Co-Diagnostics is held by insiders.
Percentage Held by Institutions
Only 14.99% of the stock of Co-Diagnostics is held by institutions.

0.6

Earnings and Valuation

Price to Earnings Ratio vs. the Market
The P/E ratio of Co-Diagnostics is -0.95, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Co-Diagnostics is -0.95, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
Co-Diagnostics has a P/B Ratio of 0.41. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

Ad InvestorPlace

The #1 Crypto for 2024

5 Tiny Cryptos That Could Soar During 2024 Crypto Bull Run One of the first ever crypto millionaires who bought Bitcoin when it was trading for just $5 in 2011 is back with his next huge prediction. A newly approved government regulation is set to flood trillions of dollars into the crypto markets, leading to the FINAL crypto bull run. One of the "Kings of Crypto" has revealed five tiny cryptos that could soar over the course of 2024. Potentially resulting in gains as big as 10X, 50X, or even 100X over the next 12 months.

Get His #1 Coin For 2024 FREE By Clicking Here

About Co-Diagnostics Stock (NASDAQ:CODX)

Co-Diagnostics, Inc., a molecular diagnostics company, develops, manufactures, and sells reagents used for diagnostic tests that function through the detection and/or analysis of nucleic acid molecules in the United States and internationally. The company offers Co-Dx PCR platform, a polymerase chain reaction (PCR) testing to patients in point-of-care and at-home setting. It also provides PCR diagnostic tests for COVID-19, influenza, tuberculosis, hepatitis B and C, human papillomavirus, malaria, chikungunya, dengue, and the zika virus. In addition, the company offers three multiplexed tests to test mosquitos for the identification of diseases carried by the mosquitos; molecular tools for detection of infectious diseases, liquid biopsy for cancer screening, and agricultural applications; tests that identify genetic traits in plant and animal genomes; and portable diagnostic device designed to bring PCR to patients in point-of-care and at-home settings. The company was incorporated in 2013 and is headquartered in Salt Lake City, Utah.

CODX Stock Price History

30 days | 90 days | 365 days | Advanced Chart

CODX Stock News Headlines

April 17, 2024 | morningstar.com

Co-Diagnostics Inc Registered Shs

April 12, 2024 | prnewswire.com

Co-Diagnostics, Inc. Inaugurates New Manufacturing Facility in Utah with Ribbon Cutting Event

April 20, 2024 | Paradigm Press (Ad)

Forget Bitcoin. Crypto Millionaire Predicts 8,788% Gains For THIS

You might have seen that Bitcoin was one of the best performing assets of 2023. It gained 164%. But a crypto millionaire who has been tracking the space for more than a decade has ABANDONED Bitcoin. He found something better.

April 4, 2024 | prnewswire.com

Co-Diagnostics, Inc. Appoints New President and Other C-Level Positions

March 21, 2024 | prnewswire.com

Co-Diagnostics, Inc. CEO Delivers Manufacturing and Commercialization Update in Conference Keynote Address

March 18, 2024 | prnewswire.com

Co-Diagnostics, Inc. CEO to Deliver Keynote Address at MarketsandMarkets 2024 in London, England

March 17, 2024 | uk.finance.yahoo.com

A Look At The Intrinsic Value Of Edel SE & Co. KGaA (ETR:EDL)

March 17, 2024 | uk.news.yahoo.com

Holby City star Rosie Marcel calls for Casualty not to kill off Charlie

April 20, 2024 | Paradigm Press (Ad)

Forget Bitcoin. Crypto Millionaire Predicts 8,788% Gains For THIS

March 16, 2024 | finance.yahoo.com

Co-Diagnostics Full Year 2023 Earnings: Misses Expectations

March 16, 2024 | finance.yahoo.com

We Think Co-Diagnostics (NASDAQ:CODX) Needs To Drive Business Growth Carefully

March 15, 2024 | finance.yahoo.com

Co-Diagnostics, Inc. (NASDAQ:CODX) Q4 2023 Earnings Call Transcript

March 15, 2024 | finance.yahoo.com

Q4 2023 Co-Diagnostics Inc Earnings Call

March 15, 2024 | markets.businessinsider.com

Maintaining Hold on Co-Diagnostics Amid Revenue Decline and Potential EUA Boost

March 15, 2024 | finance.yahoo.com

CODX Mar 2024 1.500 call

March 14, 2024 | investorplace.com

CODX Stock Earnings: Co-Diagnostics Misses EPS, Misses Revenue for Q4 2023

March 14, 2024 | benzinga.com

Co-Diagnostics: Q4 Earnings Insights

March 14, 2024 | prnewswire.com

Co-Diagnostics, Inc. Reports Full Year 2023 Financial Results

March 13, 2024 | benzinga.com

Earnings Preview: Co-Diagnostics

March 13, 2024 | markets.businessinsider.com

Here's what to expect from Co-Diagnostics's earnings

March 7, 2024 | finance.yahoo.com

Co-Diagnostics, Inc. JV CoSara Receives Clearance from Indian Regulators for Influenza Multiplex PCR Test

February 29, 2024 | morningstar.com

Co-Diagnostics Inc Registered Shs CODX

February 29, 2024 | prnewswire.com

Co-Diagnostics, Inc. Announces Fourth Quarter and Full Year 2023 Earnings Release Date and Webcast

February 15, 2024 | seekingalpha.com

CODX Co-Diagnostics, Inc.

February 1, 2024 | finance.yahoo.com

Co-Diagnostics, Inc. Shares List of Upcoming Industry Conferences and Events for February 2024

January 3, 2024 | finance.yahoo.com

Co-Diagnostics, Inc. to Host Booth at CES 2024 January 9-12

December 29, 2023 | markets.businessinsider.com

Analysts’ Opinions Are Mixed on These Healthcare Stocks: Natera (NTRA) and Co-Diagnostics (CODX)

See More Headlines

Receive CODX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Co-Diagnostics and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings: 3/14/2024
Today: 4/20/2024
Next Earnings (Estimated): 5/09/2024
Fiscal Year End: 12/31/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Sector: Medical
Industry: Surgical & medical instruments
Sub-Industry: N/A
Current Symbol: NASDAQ:CODX
CUSIP: N/A
CIK: 1692415
Web: www.codiagnostics.com
Phone: (801) 438-1036
Fax: N/A
Employees: 155
Year Founded: N/A

Price Target and Rating

Average Stock Price Target: $2.50
High Stock Price Target: $2.50
Low Stock Price Target: $2.50
Potential Upside/Downside: +117.4%
Consensus Rating: Hold
Rating Score (0-4): 2.00
Research Coverage: 1 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($1.21)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-35,330,000.00
Net Margins: -518.69%
Pretax Margin: -559.47%
Return on Equity: -35.37%
Return on Assets: -32.58%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 10.81
Quick Ratio: 10.52

Sales & Book Value

Annual Sales: $6.81 million
Price / Sales: 5.28
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $2.81 per share
Price / Book: 0.41

Miscellaneous

Outstanding Shares: 31,260,000
Free Float: 30,510,000
Market Cap: $35.95 million
Optionable: Optionable
Beta: -0.68

7 Stocks to Own Before the 2024 Election

Looking to avoid the hassle of mudslinging, volatility, and uncertainty? You'd need to be out of the market, which isn’t viable. So where should investors put their money? Find out with this report.

Get This Free Report

Key Executives

Mr. Dwight H. Egan (Age 71)
Chairman & CEO
Comp: $415.75k
Mr. Brian L. Brown CPA (Age 48)
CFO & Company Secretary
Comp: $338.92k
Mr. Richard David Abbott (Age 52)
President
Dr. Brent C. Satterfield Ph.D. (Age 47)
Co-Founder & Member of Scientific Advisory Board
Comp: $237.5k
Mr. David Nielsen
Chief Operating Officer
Mr. Dan Bohrer CPA
Vice President of Finance & Accounting
Mr. Christopher Thurston
Chief Technology Officer
Dr. Mark Poritz Ph.D.
Chief Scientific Officer
Mr. Andrew Benson
Head of Investor Relations
Dr. Mayuranki Almaula
Senior Vice President of Overseas Operations & Strategic Alliances

Key Competitors

View All Competitors

Institutional Ownership

View All Institutional Transactions

CODX Stock Analysis - Frequently Asked Questions

Should I buy or sell Co-Diagnostics stock right now?: 1 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Co-Diagnostics in the last twelve months. There are currently 1 hold rating for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" CODX shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in CODX, but not buy additional shares or sell existing shares.
View CODX analyst ratings or view top-rated stocks.
What is Co-Diagnostics' stock price target for 2024?: 1 brokerages have issued 12 month price targets for Co-Diagnostics' stock. Their CODX share price targets range from $2.50 to $2.50. On average, they anticipate the company's stock price to reach $2.50 in the next year. This suggests a possible upside of 117.4% from the stock's current price.
View analysts price targets for CODX or view top-rated stocks among Wall Street analysts.
How have CODX shares performed in 2024?: Co-Diagnostics' stock was trading at $1.33 at the start of the year. Since then, CODX stock has decreased by 13.5% and is now trading at $1.15.
View the best growth stocks for 2024 here.
Are investors shorting Co-Diagnostics?: Co-Diagnostics saw a increase in short interest during the month of March. As of March 31st, there was short interest totaling 496,500 shares, an increase of 30.1% from the March 15th total of 381,500 shares. Based on an average daily volume of 66,300 shares, the days-to-cover ratio is presently 7.5 days.
View Co-Diagnostics' Short Interest.
When is Co-Diagnostics' next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Thursday, May 9th 2024.
View our CODX earnings forecast.
How were Co-Diagnostics' earnings last quarter?: Co-Diagnostics, Inc. (NASDAQ:CODX) announced its quarterly earnings results on Thursday, March, 14th. The company reported ($0.50) earnings per share (EPS) for the quarter. The business earned $3.56 million during the quarter, compared to analyst estimates of $3.63 million. Co-Diagnostics had a negative net margin of 518.69% and a negative trailing twelve-month return on equity of 35.37%.

What other stocks do shareholders of Co-Diagnostics own?: Based on aggregate information from My MarketBeat watchlists, some companies that other Co-Diagnostics investors own include Inovio Pharmaceuticals (INO), Novavax (NVAX), Moderna (MRNA), Vaxart (VXRT), Gilead Sciences (GILD), Sorrento Therapeutics (SRNE), iBio (IBIO), Advanced Micro Devices (AMD), Pfizer (PFE) and Johnson & Johnson (JNJ).
When did Co-Diagnostics IPO?: Co-Diagnostics (CODX) raised $9 million in an initial public offering on Thursday, July 13th 2017. The company issued 1,300,000 shares at a price of $6.35-$6.75 per share. WallachBeth Capital and Network 1 Securities served as the underwriters for the IPO.
Who are Co-Diagnostics' major shareholders?: Co-Diagnostics' stock is owned by a variety of institutional and retail investors. Top institutional shareholders include SMI Advisory Services LLC (0.12%). Insiders that own company stock include Brian Lee Brown, Eugene Durenard and Reed L Benson.
View institutional ownership trends.
How do I buy shares of Co-Diagnostics?: Shares of CODX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:CODX) was last updated on 4/20/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial

Co-Diagnostics (CODX) Stock Price, News & Analysis

Co-Diagnostics MarketRank™ Stock Analysis

Overall MarketRank™

Analyst's Opinion

Short Interest

Percentage of Shares Shorted

Short Interest Ratio / Days to Cover

Change versus previous month

Dividend Strength

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score

Environmental Sustainability

News and Social Media Coverage

News Coverage This Week

Search Interest

MarketBeat Follows

Company Ownership

Earnings and Valuation

About Co-Diagnostics Stock (NASDAQ:CODX)

CODX Stock Price History

CODX Stock News Headlines

Company Calendar

Industry, Sector and Symbol

Price Target and Rating

Profitability

Debt

Sales & Book Value

Miscellaneous

Key Executives

Key Competitors

Institutional Ownership

CODX Stock Analysis - Frequently Asked Questions

Overall MarketRank^™